

chain nodes :

11 12 14 15 16 23 24 26 27 28 29 35

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

8-23 9-12 10-11 12-14 14-15 15-16 23-24 24-35 26-27 26-35 27-28 27-29

ring bonds :

1-2 1-6 2-3 3-4 3-7 4-5 4-10 5-6 7-8 8-9 9-10

exact/norm bonds :

3-7 4-10 7-8 8-9 9-10 9-12 10-11 12-14 14-15 15-16 23-24 24-35 26-27 26-35
27-28 27-29

exact bonds :

8-23

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 14:CLASS 15:CLASS 16:Atom 23:CLASS 24:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 35:CLASS

Generic attributes :

16:

Saturation : Unsaturated

=>

Uploading 09687800.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:00:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1876 TO ITERATE

53.3% PROCESSED 1000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 34923 TO 40117

PROJECTED ANSWERS: 2 TO 191

L2 2 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 17:01:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 36739 TO ITERATE

90.1% PROCESSED 33109 ITERATIONS (2 INCOMPLETE) 174 ANSWERS

100.0% PROCESSED 36739 ITERATIONS (2 INCOMPLETE) 178 ANSWERS

SEARCH TIME: 00.00.25


L3 178 SEA SSS FUL L1

=> s l3


L4 19 L3

=> d l4 1-19 bib,ab,hitstr

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:846593 CAPLUS
 TI Peptide/benzodiazepine hybrids as ligands of CCKA and CCKB receptors
 AU Escherich, Achim; Lutz, Jurgen; Escrieut, Chantal; Fourmy, Daniel; Van
 Neuren, A. Stephanie; Muller, Gerhard; Schafferhans, Andrea; Klebe,
 Gerhard; Moroder, Luis
 CS Max-Planck Institute of Biochemistry, Martinsried, 82152, Germany
 SO Biopolymers (2001), Volume Date 2000-2001, 56(2), 55-76
 CODEN: BIPMAA; ISSN: 0006-3525
 PB John Wiley & Sons, Inc.
 DT Journal
 LA English
 AB The (neuro)hormones gastrin and cholecystokinin (CCK) share a common
 C-terminal tetrapeptide amide sequence that has been recognized as the
 message portion while the N-terminal extensions are responsible for the
 CCKA and CCKB receptor subtype selectivity and avidity.
 1,4-Benzodiazepine derivs. are potent and selective antagonists of these
 receptors, and according to comparative mol. field anal., the structures
 of these nonpeptidic compds. could well mimic the message sequence of the
 peptide agonists at least in terms of spatial array of the arom. residues.
 Docking of a larger series of low mol. wt. nonpeptide antagonists to a
 homol. modeling derived CCKB receptor structure revealed a consensus
 binding mode that is further validated by data from site-directed
 mutagenesis studies of the receptors. Whether this putative binding
 pocket of the nonpeptide antagonists is identical to that of the message
 portion of the peptide agonists, or whether it is distinct and spatially
 sepd., or overlapping, but with.
 IT **404391-53-3 404391-54-4**
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological
 study)
 (peptide/benzodiazepine hybrids as ligands of CCKA and CCKB receptors)
 RN 404391-53-3 CAPLUS
 CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[4-(1-methylethoxy)phenyl]-4-oxo-2-
 quinazolinyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 404391-54-4 CAPLUS
 CN Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[4-(1-
 methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



RE.CNT 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2002 ACS

AN 2001:208250 CAPLUS

DN 134:252352

TI Preparation of 3-aryl-2-arylhureidoalkylquinazolin-4-ones and related compounds as mediators of hedgehog signaling pathways.

IN Baxter, Anthony David; Boyd, Edward Andrew; Guichert, Oivin M.; Price, Stephen; Rubin, Lee D.

PA Curis, Inc., USA

SO PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019800	A2	20010322	WO 2000-US25461	20000915
	WO 2001019800	A3	20011206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-154526P P 19990916

US 1999-159412P P 19991014

US 1999-162899P P 19991101

OS MARPAT 134:252352

AB R1LX1Y1Z1LX2Y2Z2LR2 [R1, R2 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroarylalkyl; L = null, alkyl, alkenyl, alkynyl, (CH2)nO(CH2)p, etc.; n, p = 0-10; X1, X2 = NR8, O, S, Se, N:N, ON:CH, heterocyclyl, bond, etc.; Y1, Y2 = CO, CS, SO2, SO, C(:NCN), heteroaryl, bond, etc.; Z1, Z2 = NR8, O, S, Se, N:N, ON:CH, heterocyclyl, bond, etc.; R8 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroaralkyl, etc.], were prepd. Thus, triphosgene in EtOAc was added to 4-nitro-3-trifluoromethylaniline in EtOAc followed by stirring and reflux. The mixt. was concd., dissolved in CHCl3, and treated with 3-(4-fluorophenyl)-2-(1-methylaminoethyl)-4-oxo-3,4-dihydroquinazoline in CHCl3 to give 97% 1-[1-[3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]-3-(3-trifluoromethyl-4-nitrophenyl)-1-methylurea. The latter inhibited sonic hedgehog-induced Gli transcription activity with IC50 <5 .mu.M.

IT 330796-20-8P 330796-21-9P 330796-24-2P

330796-25-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 3-aryl-2-arylhureidoalkylquinazolin-4-ones and related compds. as mediators of hedgehog signaling pathways)

RN 330796-20-8 CAPLUS


CN Urea, N-[2-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Amplified




RN 330796-21-9 CAPLUS

CN Urea, N-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 330796-24-2 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 330796-25-3 CAPLUS

CN Urea, N-(2,6-dichloro-4-pyridinyl)-N'-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2002 ACS

AN 1998:352629 CAPLUS

DN 129:27954

TI Quinazolinone derivatives as cholecystokinin (CCK) ligands

IN Padia, Janak Khimchand

PA Warner-Lambert Co., USA

SO U.S., 23 pp. Cont.-in-part of U.S. Ser. No. 287,454.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5756502	A	19980526	US 1995-500436	19950710
	US 5869665	A	19990209	US 1997-826843	19970408
PRAI	US 1994-287454		19940808		
	US 1995-500436		19950710		

OS CASREACT 129:27954; MARPAT 129:27954

AB The title compds. [I; W, X, Y, Z = CR3, CR4, CR5, CR6, N, etc.; M = O, S; B = bond or (un)substituted alkylene; A = R1NCO(CH2)n, CONR11(CH2)n, etc.; n = 0, 1; R1, R2 = C1-6 alkyl, (un)substituted aryl, etc.; R3-R6 = H, OH, alkoxy, etc.; R11 = H, lower alkyl] are prepd. I with good binding affinity for the CCK-A and CCK-B receptors are useful agents to suppress appetite, reduce gastric acid secretion, and the like. Thus, 2-(aminomethyl)-3-[3-(methylethoxy)phenyl]-4(3H)-quinazoline (prepn. given) was reacted with 3-methylphenyl isocyanate to give 50% the title compd. (II), which showed CCK-A and CCK-B receptor binding affinities (Ki) of 1637 and 879 nm resp.

IT 189937-54-0P 189937-57-3P 189937-58-4P

189937-60-8P 189937-63-1P 189937-64-2P


189937-66-4P 207978-49-2P 207978-50-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(quinazolinone derivs. as cholecystokinin (CCK) ligands)


RN 189937-54-0 CAPLUS

CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 189937-57-3 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 189937-58-4 CAPLUS

CN Urea, N-[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 189937-60-8 CAPLUS

CN Benzoic acid, 3-[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 189937-63-1 CAPLUS

CN Benzenesulfonamide, N-[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]amino]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 189937-64-2 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 189937-66-4 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 207978-49-2 CAPLUS

CN Benzoic acid, 2-[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 207978-50-5 CAPLUS

CN Benzoic acid, 2-[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:169718 CAPLUS
 DN 128:238969
 TI Novel Nonpeptide CCK-B Antagonists: Design and Development of
 Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B
 Antagonists
 AU Padia, Janak K.; Field, Mark; Hinton, Joanna; Meecham, Ken; Pablo, Julius;
 Pinnock, Rob; Roth, Bruce D.; Singh, Lakhbir; Suman-Chauhan, Nirmala;
 Trivedi, Bharat K.; Webdale, Louise
 CS Departments of Chemistry and of Pharmacokinetics and Drug Metabolism,
 Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company,
 Ann Arbor, MI, 48105, USA
 SO J. Med. Chem. (1998), 41(7), 1042-1049
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Urea-linked quinazolines [I; R = (un)substituted Ph, cyclohexyl; R1 =
 (un)substituted Ph, 3-pyridyl, 1-naphthyl] were prepd. as selective
 orally active CCK-B antagonists. Thus, thioxoquinazolinones II (prepd.
 from anthranilic acid and the requisite isothiocyanate) were treated with
 hydrazine gave the 2-hydrazino compds. which were then treated with an
 isocyanate to give I. Representative compds. of this series were tested
 in the functional assay, i.e., guinea pig stomach strip assay, and showed
 pure antagonist profiles. I [R = 3-(tert-butoxycarbonyl)phenyl, R1 =
 3-isopropoxyphenyl] and I [R = 3-cyanophenyl, R1 = 3-
 (dimethylamino)phenyl] (III) were orally active in the elevated rat X-maze
 test and showed dose-dependent anxiolytic-like action. These compds. were
 also evaluated for their pharmacokinetic profile. The abs. oral
 bioavailability of III was 22% in rats.
 IT 180423-04-5P 180423-05-6P 180423-06-7P
 180423-07-8P 180423-08-9P 180423-09-0P
 180423-10-3P 180423-11-4P 180423-13-6P
 180423-14-7P 180423-15-8P 180423-16-9P
 180423-17-0P 180423-18-1P 180423-21-6P
 180423-22-7P 180423-23-8P 180423-24-9P
 180423-25-0P 180423-26-1P 180423-27-2P
 180423-29-4P 180423-32-9P 180423-33-0P
 180423-34-1P 180423-35-2P 180423-36-3P
 180423-37-4P 180423-38-5P 180423-39-6P
 180423-41-0P 180423-44-3P 180423-45-4P
 180423-46-5P 189937-57-3P 189937-64-2P
 189937-66-4P 205063-59-8P 205063-61-2P
 205063-64-5P 205063-66-7P 205063-71-4P
 205063-80-5P 205063-88-3P 205063-98-5P
 205064-08-0P 205064-19-3P 205064-22-8P
 205064-24-0P 205064-27-3P 205064-29-5P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of urea-linked quinazolinones as selective CCK-B receptor
 antagonists)
 RN 180423-04-5 CAPLUS
 CN Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[3-(1-
 methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-05-6 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-06-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-07-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-08-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-09-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 180423-10-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 180423-11-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-13-6 CAPLUS

CN Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-14-7 CAPLUS

CN Benzoic acid, 2-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-15-8 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 180423-16-9 CAPLUS

CN Hydrazinecarboxamide, N-(4-chlorophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-17-0 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 180423-18-1 CAPLUS

CN Hydrazinecarboxamide, N-cyclohexyl-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-21-6 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-


09/724,277 (09/687,800)

quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-22-7 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3,4-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-23-8 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-24-9 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(1-naphthalenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-25-0 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-26-1 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-27-2 CAPLUS

CN Benzoic acid, 3-[[[2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-29-4 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-32-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-33-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3,4-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-34-1 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-35-2 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(1-naphthalenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-36-3 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-37-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-38-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-39-6 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-aminophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-41-0 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-44-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-45-4 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-46-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 189937-57-3 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 189937-64-2 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 189937-66-4 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 205063-59-8 CAPLUS

CN Hydrazinecarboxamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 205063-61-2 CAPLUS

CN Hydrazinecarboxamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-64-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-66-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(2,3-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-71-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-80-5 CAPLUS

CN Benzoic acid, 3-[[[2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 205063-88-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(2,3-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 205063-98-5 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 205064-08-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 205064-19-3 CAPLUS

CN Hydrazinecarboxamide, N-(3-chlorophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 205064-22-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 205064-24-0 CAPLUS


CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 205064-27-3 CAPLUS


CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)- (9CI) (CA INDEX NAME)

09/724,277 (09/687,800)




RN 205064-29-5 CAPLUS


CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3-(3-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:285638 CAPLUS
 DN 126:343533
 TI Design and synthesis of novel nonpeptide CCK-B receptor antagonists
 AU Padia, J. K.; Chilvers, H.; Daum, P.; Pinnock, R.; Suman-Chauhan, N.;
 Webdale, L.; Trivedi, B. K.
 CS Division of Warner-Lambert Company, Department of Chemistry, Parke-Davis
 Pharmaceutical Research, Ann Arbor, MI, 48105, USA
 SO Bioorg. Med. Chem. Lett. (1997), 7(7), 805-810
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier
 DT Journal
 LA English
 AB A novel hybrid series of nonpeptide CCK-B receptor antagonists,
 quinazolinones I (R = 3-Me, 4-Br, 3-CO₂Et, etc., L = CH₂, CH₂CH₂, X = O,
 S, Y = NH, NHCH₂, NHSO₂), has been designed from two known series derived
 from asperlicin. An efficient synthesis of 2-aminoquinazolinone, an
 intermediate for the synthesis of a targeted analog, has been developed.
 IT 189937-54-0P 189937-57-3P 189937-58-4P
 189937-59-5P 189937-60-8P 189937-62-0P
 189937-63-1P 189937-64-2P 189937-66-4P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and CCK-B receptor antagonist activity of quinazolinones)
 RN 189937-54-0 CAPLUS
 CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-
 quinazolinyl]methyl]-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 189937-57-3 CAPLUS
 CN Urea, N-(4-bromophenyl)-N'-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-
 oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 189937-58-4 CAPLUS
 CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-
 quinazolinyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

NAME)




RN 189937-59-5 CAPLUS

CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 189937-60-8 CAPLUS

CN Benzoic acid, 3-[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 189937-62-0 CAPLUS

CN Urea, N-[(4-bromophenyl)methyl]-N'-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 189937-63-1 CAPLUS

CN Benzenesulfonamide, N-[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]amino]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 189937-64-2 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 189937-66-4 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:132331 CAPLUS
 DN 126:186050
 TI N-unsubstituted sulfenamides by electrophilic amination of mercapto compounds
 AU Andrae, Siegfried
 CS Institut Angewandte Chemie Adlershof e.V., Berlin, D-12489, Germany
 SO J. Prakt. Chem./Chem.- Ztg. (1997), 339(2), 152-158
 CODEN: JPCCEM; ISSN: 0941-1216
 PB Barth
 DT Journal
 LA English
 OS CASREACT 126:186050
 AB Mercapto compds. derived from 2- and 4-thiouracils, pyridines, and pyridine 1-oxide were aminated by 1-oxa-2-azaspiro[2.5]octane (I) to give sulfenamides and isothiazolopyridine, resp., which add to phenylisocyanates forming sulfenylureas. Several other mercapto compds. yielded disulfides on treatment with I. Attempts of oxidn. of the sulfenamides and sulfenylureas were unsuccessful.
 IT **137081-49-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of sulfenamides by thiol amination)
 RN 137081-49-3 CAPLUS
 CN 2-Quinazolinesulfenamide, 3,4-dihydro-4-oxo-3-phenyl-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:527667 CAPLUS
 DN 125:168015
 TI Preparation of quinazolinones as cholecystokinin (CCK) antagonists
 IN Padia, Janak Khimchand
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9620178	A1	19960704	WO 1995-US15918	19951206
	W: CA, EE, JP, LT, LV, MX, SI RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1994-364624		19941227		
	US 1995-545241		19951121		
OS	MARPAT 125:168015				
AB	The title compds. [I; W, X, Y, Z = (substituted) CH, N and no more than two of them are N; M = O, S; A = (N-substituted) NHCO(CH ₂) _n , NHCOO(CH ₂) ₂ , NHCONH(CH ₂) _n , etc.; R ₁ , R ₂ = C1-6 alkyl, (substituted) Ph, heteroaryl, etc.; n = 0-1] with good binding affinity for the CCK-A and CCK-B receptors and useful to suppress appetite, reduce gastric acid secretion and anxiety, to treat gastrointestinal ulcers, psychosis and pain, and to block drug or alc. withdrawal reaction, were prepd. Thus, reaction of hydrazine II with 4-BrC ₆ H ₄ NCO in MeCN afforded 47% I [W, X, Y, Z = CH; M = O; A = NHCONH; R ₁ = 4-BrC ₆ H ₄ ; R ₂ = 3-iPrOC ₆ H ₄] which showed K _i of 3432 nM against CCK-A and 16.0 nM against CCK-B.				
IT	180423-10-3P RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of quinazolinones as cholecystokinin (CCK) antagonists)				
RN	180423-10-3 CAPLUS				
CN	Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				



IT 180423-04-5P 180423-05-6P 180423-06-7P
 180423-07-8P 180423-08-9P 180423-09-0P
 180423-11-4P 180423-12-5P 180423-13-6P
 180423-14-7P 180423-15-8P 180423-16-9P
 180423-17-0P 180423-18-1P 180423-19-2P
 180423-20-5P 180423-21-6P 180423-22-7P
 180423-23-8P 180423-24-9P 180423-25-0P


180423-26-1P 180423-27-2P 180423-28-3P
 180423-29-4P 180423-30-7P 180423-31-8P
 180423-32-9P 180423-33-0P 180423-34-1P
 180423-35-2P 180423-36-3P 180423-37-4P
 180423-38-5P 180423-39-6P 180423-41-0P
 180423-42-1P 180423-43-2P 180423-44-3P
 180423-45-4P 180423-46-5P 180423-47-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazolinones as cholecystokin (CCK) antagonists)


RN 180423-04-5 CAPLUS

CN Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-05-6 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-06-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-07-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-08-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-09-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 180423-11-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-12-5 CAPLUS

CN Hydrazinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-13-6 CAPLUS

CN Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-14-7 CAPLUS

CN Benzoic acid, 2-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-15-8 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 180423-16-9 CAPLUS

CN Hydrazinecarboxamide, N-(4-chlorophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-17-0 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-18-1 CAPLUS

CN Hydrazinecarboxamide, N-cyclohexyl-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-19-2 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-20-5 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(2-ethylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-21-6 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-22-7 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3,4-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-23-8 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-24-9 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(1-naphthalenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-25-0 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-26-1 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)





RN 180423-27-2 CAPLUS

CN Benzoic acid, 3-[[[2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-28-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[4-(4-morpholinylsulfonyl)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-29-4 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-30-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-31-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(2-ethylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-32-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-33-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3,4-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-34-1 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-35-2 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(1-naphthalenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-36-3 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-37-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-38-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-39-6 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-aminophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-41-0 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-42-1 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-43-2 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-[3-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 180423-44-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(4-methoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 180423-45-4 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-46-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-


09/724,277 (09/687,800)

quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-47-6 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1994:217516 CAPLUS
 DN 120:217516
 TI Synthesis and reaction of 2-ethoxycarbonyl-4(3H)-quinazolinone with
 nitrogen nucleophiles
 AU Amine, M. S.; El-Hashash, M. A.; Attia, I. A.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Indian J. Chem., Sect. B (1993), 32B(5), 577-80
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 AB 2-Ethoxycarbonyl-4(3H)-quinazolinone (I; R = OEt) reacts with piperidine,
 methylamine and anthranilic acid to give the Mannich bases, e.g. II and
 III, and 4H-3,1-benzoxazin-4-one derivs., e.g. IV. The behavior of the
 latter towards some nitrogen nucleophiles has been described. Compd. I (R
 = OEt) also reacts with hydrazine and gives the corresponding hydrazide
 (I; R = NHNH₂), the behavior of which towards aldehydes, ketones, and Ph
 isocyanate has also been discussed.
 IT **153776-85-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as intermediate in reaction of ethoxycarbonylquinazolinone
 with nitrogen nucleophiles)
 RN 153776-85-3 CAPLUS
 CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-3-[(phenylamino)carbonyl]-
 , 2-[(phenylamino)carbonyl]hydrazide (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1991:632271 CAPLUS
 DN 115:232271
 TI Preparation of 3-substituted 2-aminothio-4-oxo-3,4-dihydroquinazolines as fungicides
 IN Andreae, Siegfried; Schmitz, Ernst
 PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
 SO Ger. (East), 4 pp.
 CODEN: GEXXA8
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 289525	A5	19910502	DD 1989-325853	19890217
OS	MARPAT 115:232271				
AB	The title compds. [I; R = (un)substituted (ar)alkyl, alkenyl, (hetero)aryl; R1R2 = bond; R3 = NH2] were prepd. as fungicides (no data) by treatment of I (R1 = H, R2R3 = bond) with 3,3-pentamethylenoxaziridine.				
IT	137081-49-3P RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	137081-49-3 CAPLUS				
CN	2-Quinazolinesulfenamide, 3,4-dihydro-4-oxo-3-phenyl-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)				




L4 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1986:207299 CAPLUS
 DN 104:207299
 TI 2-Substituted 3,4-dihydroquinazolin-4-ones
 IN Kottka, Karl; Kuehmstedt, Hans; Knoke, Dagmar; Wehlan, Helmut; Heder, Gottfried; Siems, Wolf Eberhard
 PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
 SO Ger. (East), 14 pp.
 CODEN: GEXXA8
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 225131	A1	19850724	DD 1984-259720	19840130
OS	CASREACT 104:207299				
AB	Antihypertensive (no data) 2-anilino-4(3H)-quinazolinones I (R1 = Ph, XC6H4; R2 = H, halo; R3 = H; X = Br, Cl) were prepd. by deamination of I (R3 = NH2). Thus, I (R1 = 4-BrC6H4, R2 = 6-Br, R3 = NH2) was stirred at 0-5.degree. in aq. HCl while aq. NaNO2 was added dropwise to give, after 3 h agitation, 95% I (R1 = 4-BrC6H4, R2 = 6-Br, R3 = H). Inhibitory activity of 40 other 2-substituted 3(4H)-quinazolinones against angiotensin I-converting enzyme (IC50) is reported and their structure-activity relationship is discussed.				
IT	77747-37-6 77775-32-7 101164-48-1 RL: RCT (Reactant) (angiotensin-converting enzyme inhibition by, structure in relation to)				
RN	77747-37-6 CAPLUS				
CN	Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)				





RN 77775-32-7 CAPLUS
 CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 101164-48-1 CAPLUS

09/724,277 (09/687,800)


CN Hydrazinecarboxamide, 2-[3,4-dihydro-4-oxo-3-[4-(pentyloxy)phenyl]-2-quinazolinyl]-N-naphthalenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1984:114567 CAPLUS
 DN 100:114567
 TI New quinazolinones as monoamine oxidase inhibitors
 AU Bahadur, Surendra; Saxena, Mukta; Agarwal, J. C.; Shanker, Kirpa
 CS Dep. Chem., Univ. Lucknow, Lucknow, 226 007, India
 SO Indian J. Pharm. Sci. (1983), 45(3), 121-3
 CODEN: IJSIDW; ISSN: 0250-474X
 DT Journal
 LA English
 AB The 28 quinazolines I (R = H, Me; R1 = R2 = H, Br; R3 = H, 4-Cl, 4-Me, 3-Me, 4-OMe) were tested for monoamine oxidase [9001-66-5] inhibitory activity in rat brain homogenates. The most active compd., I (R = Me; R1 = R2 = H; R3 = 4-OMe) [84793-77-1], caused 82.8% inhibition at 10-3M. Five compds. caused 68.5-77.1% inhibition, and 5 appeared completely inactive. Structure-activity relations are discussed.
 IT 84793-60-2 84793-60-2D, derivs. 84793-61-3
 84793-62-4 84793-63-5 84793-64-6
 84793-65-7 84793-66-8 84793-67-9
 84793-68-0 84793-69-1 84793-70-4
 84793-71-5 84793-72-6 84793-73-7
 84793-74-8 84793-75-9 84793-76-0
 84793-77-1 84793-78-2 84793-79-3
 84793-80-6 84793-81-7 84793-82-8
 84793-83-9 84793-84-0 84793-85-1
 84793-86-2 84793-87-3
 RL: BIOL (Biological study)
 (monoamine oxidase inhibition by, structure in relation to)
 RN 84793-60-2 CAPLUS
 CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-60-2 CAPLUS
 CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-61-3 CAPLUS
 CN Acetamide, 2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-

[[(4-phenoxyphenyl) amino] carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-62-4 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-63-5 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-64-6 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-65-7 CAPLUS

CN Acetamide, 2-[(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-66-8 CAPLUS

CN Acetamide, 2-[[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-67-9 CAPLUS

CN Acetamide, 2-[[6-bromo-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-68-0 CAPLUS

CN Acetamide, 2-[[6-bromo-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-69-1 CAPLUS

CN Acetamide, 2-[[6-bromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-70-4 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-71-5 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-72-6 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-73-7 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-74-8 CAPLUS

CN Acetamide, 2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-75-9 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-76-0 CAPLUS

CN Acetamide, 2-[[[3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-77-1 CAPLUS

CN Acetamide, 2-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 84793-78-2 CAPLUS


CN Acetamide, 2-[[[6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 84793-79-3 CAPLUS


CN Acetamide, 2-[[[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-

quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-80-6 CAPLUS

CN Acetamide, 2-[[[6-bromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-81-7 CAPLUS

CN Acetamide, 2-[[[6-bromo-3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-82-8 CAPLUS

CN Acetamide, 2-[[[6-bromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-83-9 CAPLUS

CN Acetamide, 2-[[[6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-84-0 CAPLUS

CN Acetamide, 2-[[[6,8-dibromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-85-1 CAPLUS

CN Acetamide, 2-[[[6,8-dibromo-3-(4-methylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-86-2 CAPLUS


CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-87-3 CAPLUS
CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)



L4 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1983:558378 CAPLUS
 DN 99:158378
 TI Synthesis of 2-hydrazino-3-naphthyl-substituted 3,4-dihydroquinazolin-4-ones and their cyclization products. Part 9: Synthesis of compounds with aminoguanidine structure
 AU Kottke, K.; Kuehmstedt, H.; Griesner, G.
 CS Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ger. Dem. Rep.
 SO Pharmazie (1983), 38(6), 367-8
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 OS CASREACT 99:158378
 AB Hydrazinoquinazolinones I (R = 1- or 2-naphthyl, R1 = H), prepd. by hydrazinolysis of the corresponding 2-thioxo derivs., were condensed with R2NCX1 (R2 = Ph, 1- or 2-naphthyl; X1 = O, S) to give semicarbazides I [R1 = C(X1)NHR2] and cyclocondensed with carboxylic acid derivs., (H2N)2CO, CS2, etc., to give II [X = N, CR3 (R3 = H, Me, Et, Pr, Bu, CO2Et, CH2CO2Et, SH)].
 IT **87466-06-6P 87466-08-8P 87466-09-9P 87466-10-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 87466-06-6 CAPLUS
 CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(1-naphthalenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 87466-08-8 CAPLUS
 CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(2-naphthalenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 87466-09-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(1-naphthalenyl)-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 87466-10-2 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(2-naphthalenyl)-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1983:470757 CAPLUS
 DN 99:70757
 TI 1,4,7,9-Differently substituted 4,5-dihydro-s-triazolo[4,3-a]quinazolin-5-ones
 IN Kottke, Karl; Kuehmstedt, Hans; Hagen, Volker; Renner, Helga; Schnitzler, Stephan
 PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
 SO Ger. (East), 27 pp.
 CODEN: GEXXA8
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 158549	Z	19830119	DD 1981-229905	19810513
AB	Triazoloquinazolinones I [R, R1 = H, alkyl, halo, alkoxy, alkylthio; R2 = H, OH, SH, alkoxy, alkylthio, amino, (un)substituted alkyl, aryl, etc.; R3 = H, alkyl, (un)substituted aryl] were prepd. Thus, 3-(3-methylphenyl-2-hydrazino-4(3H)quinazolinolinone was cyclocondensed with HCO2H to give 92% I (R = R1 = H, R2 = OH, R3 = 3-MeC6H4) (II). II gave 30% inhibition of passive cutaneous anaphylaxis in rats.				
IT	77747-37-6P 77747-38-7P 77747-39-8P 77775-32-7P 85773-38-2P 85773-39-3P 85773-40-6P 85773-41-7P 85773-42-8P 85773-49-5P 85773-50-8P 85773-52-0P 85773-53-1P 85773-54-2P 85773-55-3P 86506-94-7P 86506-95-8P 86506-98-1P 86506-99-2P 86507-00-8P 86513-40-8P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and cyclization of)				
RN	77747-37-6 CAPLUS				
CN	Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)				




RN 77747-38-7 CAPLUS
 CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 77747-39-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 77775-32-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-38-2 CAPLUS

CN Hydrazinecarboxamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-39-3 CAPLUS

CN Hydrazinecarboxamide, 2-(6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-40-6 CAPLUS

CN Hydrazinecarboxamide, 2-(6-chloro-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 85773-41-7 CAPLUS


CN Hydrazinecarboxamide, 2-[3-(4-butoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 85773-42-8 CAPLUS


CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[4-(3-methylbutoxy)phenyl]-4-oxo-2-

quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-49-5 CAPLUS

CN Hydrazinecarboxamide, 2-[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-50-8 CAPLUS

CN Hydrazinecarboxamide, 2-[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-52-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[4-(3-methylbutoxy)phenyl]-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-53-1 CAPLUS

CN Hydrazinecarboxamide, 2-(6-chloro-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-54-2 CAPLUS

CN Hydrazinecarboxamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-55-3 CAPLUS

CN Hydrazinecarboxamide, 2-(6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)





RN 86506-94-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-6-iodo-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 86506-95-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-chlorophenyl)-3,4-dihydro-6-iodo-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 86506-98-1 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-butylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 86506-99-2 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(2-chlorophenyl)-3,4-dihydro-6-iodo-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 86507-00-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-6-iodo-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 86513-40-8 CAPLUS


CN Hydrazinecarboxamide, 2-[3-(3-chlorophenyl)-3,4-dihydro-6-iodo-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1983:198151 CAPLUS
 DN 98:198151
 TI Synthesis of compounds with aminoguanidine structure. Part 8.
 1,4,7,9-Substituted 4,5-dihydro-s-triazolo[4,3-a]quinazolin-5-ones and
 4,5-dihydrotetrazolo[1,5-a]quinazolin-5-ones
 AU Kottke, K.; Kuehmstedt, H.; Knoke, D.
 CS Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, Ger. Dem. Rep.
 SO Pharmazie (1983), 38(1), 25-8
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 OS CASREACT 98:198151
 AB Triazoloquinazolinones I [R1 = Me, MeO, BuO, Cl, Br, 4-F, isoamyloxy, Me2;
 R2 = H, Cl, Br; R3 = H, Br; X = CH, CMe, COH, CSR4 (R4 = H, Et, Pr), CNH2,
 CCH2Cl, CPh, CCH2CO2Et, etc.] and tetrazoloquinazolinones I [R1 = BuO,
 Me2, H; R2 = H, Cl, Br; R3 = H, Cl; X = N] were prepd. by reaction of
 hydrazinoquinazolinones II with carboxylic acids, alkanoyl chlorides,
 COCl2, CSCl2, BrCN, and dialkyl alkanedicarboxylates.
 IT 77747-37-6P 77747-38-7P 77747-39-8P
 77775-32-7P 85773-38-2P 85773-39-3P
 85773-40-6P 85773-41-7P 85773-42-8P
 85773-48-4P 85773-49-5P 85773-50-8P
 85773-52-0P 85773-53-1P 85773-54-2P
 85773-55-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 77747-37-6 CAPLUS
 CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-
 quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77747-38-7 CAPLUS
 CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-
 quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 77747-39-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 77775-32-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-38-2 CAPLUS

CN Hydrazinecarboxamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-39-3 CAPLUS

CN Hydrazinecarboxamide, 2-(6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-40-6 CAPLUS

CN Hydrazinecarboxamide, 2-(6-chloro-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 85773-41-7 CAPLUS


CN Hydrazinecarboxamide, 2-[3-(4-butoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 85773-42-8 CAPLUS


CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[4-(3-methylbutoxy)phenyl]-4-oxo-2-

quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-48-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-butoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-49-5 CAPLUS

CN Hydrazinecarboxamide, 2-[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-50-8 CAPLUS

CN Hydrazinecarboxamide, 2-[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-52-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[4-(3-methylbutoxy)phenyl]-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-53-1 CAPLUS

CN Hydrazinecarboxamide, 2-(6-chloro-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-54-2 CAPLUS

CN Hydrazinecarboxamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-55-3 CAPLUS


CN Hydrazinecarboxamide, 2-(6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1983:107242 CAPLUS
 DN 98:107242
 TI Synthesis of 4(3H)-quinazolinones as antimicrobial agents
 AU Bahadur, Surendara; Saxena, Mukta
 CS Chem. Dep., Lucknow Univ., Lucknow, 226007, India
 SO J. Chem. Soc. Pak. (1982), 4(3), 141-5
 CODEN: JCSPDF
 DT Journal
 LA English
 AB Quinazolinones I (R, R1 = H, Br; R2 = H, 4-Cl, 3-Me, 4-Me, 4-MeO; R3 = H) were prep'd. by treating 2,3,5-(H2N)RR1C6H2CO2H with R2C6H4NCS. I reacted with ClCH2CONHCONHC6H4OR4-4 (R4 = Ph, 4-MeC6H4) (II) to give I (R3 = CH2CONHCONHC6H4OR4-4). II were prep'd. by treating 4-R4OC6H4NH2 with KCNO to give a urea deriv., followed by reaction with ClCH2COCl. I are effective against gram-pos. bacteria and are marginally effective against *Aspergillus niger* and *Helminthosporium* species.
 IT **84793-60-2P 84793-61-3P 84793-62-4P**
84793-63-5P 84793-64-6P 84793-65-7P
84793-66-8P 84793-67-9P 84793-68-0P
84793-69-1P 84793-70-4P 84793-71-5P
84793-72-6P 84793-73-7P 84793-74-8P
84793-75-9P 84793-76-0P 84793-77-1P
84793-78-2P 84793-79-3P 84793-80-6P
84793-81-7P 84793-82-8P 84793-83-9P
84793-84-0P 84793-85-1P 84793-86-2P
84793-87-3P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and bactericidal and fungicidal activity of)
 RN 84793-60-2 CAPLUS
 CN Acetamide, 2-[[3-(4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-61-3 CAPLUS
 CN Acetamide, 2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-62-4 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]N-
[[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)


RN 84793-63-5 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]N-
[[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)


RN 84793-64-6 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]N-
N-[[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)


RN 84793-65-7 CAPLUS

CN Acetamide, 2-[(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]N-
[[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)


RN 84793-66-8 CAPLUS
 CN Acetamide, 2-[[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-67-9 CAPLUS
 CN Acetamide, 2-[[6-bromo-3-(4-methylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 84793-68-0 CAPLUS
 CN Acetamide, 2-[[6-bromo-3-(3-methylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-69-1 CAPLUS
 CN Acetamide, 2-[[6-bromo-3-(4-methoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[4-phenoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-70-4 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]thio]-N-[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-71-5 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-72-6 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(4-phenoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-73-7 CAPLUS

CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-74-8 CAPLUS

CN Acetamide, 2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-75-9 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-76-0 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-77-1 CAPLUS

CN Acetamide, 2-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-78-2 CAPLUS

CN Acetamide, 2-[[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-79-3 CAPLUS

CN Acetamide, 2-[[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-80-6 CAPLUS

CN Acetamide, 2-[[6-bromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-81-7 CAPLUS

CN Acetamide, 2-[[6-bromo-3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-82-8 CAPLUS

CN Acetamide, 2-[[6-bromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-83-9 CAPLUS

CN Acetamide, 2-[(6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 84793-84-0 CAPLUS

CN Acetamide, 2-[[[6,8-dibromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-85-1 CAPLUS

CN Acetamide, 2-[[[6,8-dibromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-86-2 CAPLUS

CN Acetamide, 2-[[[6,8-dibromo-3,4-dihydro-3-(3-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)




RN 84793-87-3 CAPLUS


CN Acetamide, 2-[[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[[4-(4-methylphenoxy)phenyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)



L4 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1982:582336 CAPLUS
 DN 97:182336
 TI Synthesis and evaluation of substituted 4(3H)-quinazolone derivatives for antimicrobial and antiacetylcholinesterase activities
 AU Misra, H. K.; Gupta, A. K. Sen
 CS Chem. Dep., Lucknow Univ., Lucknow, 226007, India
 SO Pharmazie (1982), 37(4), 254-6
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA English
 AB Etherification of mercaptoquinazolones I (R = H) with ClCH₂CONHCONHC₆H₄R₂ gave 51-79% 27 carbamoylmethylthioquinazolones I (R = CH₂CONHCONHC₆H₄R₂, R₂ = p-Br, o-, m-, p-Me, o-MeO, o-Et; R₁ = o-Me, m-, p-MeO). At 10 ppm, I (R₁ = o-Me, R₂ = p-Me) gave 90.5% inhibition of *Aspergillus niger* growth in the agar diln. test after 1 wk.
 IT 83315-77-9P 83315-78-0P 83315-79-1P
 83315-80-4P 83315-81-5P 83315-82-6P
 83315-83-7P 83315-84-8P 83315-85-9P
 83315-86-0P 83315-87-1P 83315-88-2P
 83315-89-3P 83315-90-6P 83315-91-7P
 83315-92-8P 83315-93-9P 83315-94-0P
 83315-95-1P 83315-96-2P 83315-97-3P
 83315-98-4P 83315-99-5P 83316-00-1P
 83316-01-2P 83334-53-6P 83380-52-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and antimicrobial and antiacetylcholinesterase activities of)
 RN 83315-77-9 CAPLUS
 CN Acetamide, 2-[[[6,8-dibromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)





RN 83315-78-0 CAPLUS
 CN Acetamide, N-[[[(3-chlorophenyl)amino]carbonyl]-2-[[[6,8-dibromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)





RN 83315-79-1 CAPLUS

CN Acetamide, N-[[(4-chlorophenyl) amino] carbonyl]-2-[[6,8-dibromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)




RN 83315-80-4 CAPLUS

CN Acetamide, N-[[(4-bromophenyl) amino] carbonyl]-2-[[6,8-dibromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)




RN 83315-81-5 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[(2-methylphenyl) amino] carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-82-6 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(3-methylphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-83-7 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(4-methylphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-84-8 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(2-ethylphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-85-9 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-86-0 CAPLUS

CN Acetamide, N-[[3-(3-chlorophenyl)amino]carbonyl]-2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)




RN 83315-87-1 CAPLUS

CN Acetamide, N-[[4-chlorophenyl)amino]carbonyl]-2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)




RN 83315-88-2 CAPLUS

CN Acetamide, N-[[(4-bromophenyl) amino] carbonyl]-2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)





RN 83315-89-3 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[(2-methylphenyl) amino] carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-90-6 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[(3-methylphenyl) amino] carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-91-7 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[4-methylphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-92-8 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[2-methoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-93-9 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[2-ethylphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-94-0 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-95-1 CAPLUS

CN Acetamide, N-[[[(3-chlorophenyl)amino]carbonyl]-2-[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)




RN 83315-96-2 CAPLUS

CN Acetamide, N-[[[(4-chlorophenyl)amino]carbonyl]-2-[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)




RN 83315-97-3 CAPLUS

CN Acetamide, N-[[(4-bromophenyl) amino] carbonyl]-2-[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)




RN 83315-98-4 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[(2-methylphenyl) amino] carbonyl]- (9CI) (CA INDEX NAME)




RN 83315-99-5 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[(3-methylphenyl) amino] carbonyl]- (9CI) (CA INDEX NAME)




RN 83316-00-1 CAPLUS

CN Acetamide, 2-[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[[(4-methylphenyl) amino] carbonyl]- (9CI) (CA INDEX NAME)




RN 83316-01-2 CAPLUS

CN Acetamide, 2-[[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(2-methoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 83334-53-6 CAPLUS

CN Acetamide, 2-[[[6,8-dibromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(2-methoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 83380-52-3 CAPLUS


CN Acetamide, 2-[[[6,8-dibromo-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]thio]-N-[(2-ethylphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1982:30631 CAPLUS
 DN 96:30631
 TI Monoamine oxidase and succinate dehydrogenase inhibitory properties of substituted mercaptoquinazolones
 AU Mehrotra, Suman; Barthwal, J. P.; Saxena, A. K.; Bhargava, K. P.; Parmar, S. S.
 CS King George's Med. Coll., Lucknow Univ., Lucknow, 226003, India
 SO J. Heterocycl. Chem. (1981), 18(6), 1157-9
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 AB Twelve 6-substituted-2-(1'-mercaptoacetyl-3'-arylurea)-3-phenyl-4-quinazolones were synthesized by condensation of 6-substituted anthranilic acids and aryl isothiocyanates followed by reaction with chloroacetylaryllurea. All compds. were evaluated for their enzyme inhibitory activity. All substituted quinazolones at a final concn. of 2 .times. 10⁻⁴ M inhibited in vitro the monoamine oxidase and succinate dehydrogenase activities of rat brain homogenates; the degree of inhibition of the resp. enzymes was 11-77% and 25-53%.
 IT 80416-38-2P 80416-39-3P 80416-40-6P
 80416-41-7P 80416-42-8P 80416-43-9P
 80416-44-0P 80416-45-1P 80416-46-2P
 80416-47-3P 80416-48-4P 80416-49-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and enzyme inhibition by)
 RN 80416-38-2 CAPLUS
 CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 80416-39-3 CAPLUS
 CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[(2-methylphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-40-6 CAPLUS
 CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[(3-methylphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-41-7 CAPLUS

CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[(2-methoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-42-8 CAPLUS

CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[(3-methoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-43-9 CAPLUS

CN Acetamide, N-[(4-chlorophenyl)amino]carbonyl]-2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]- (9CI) (CA INDEX NAME)




RN 80416-44-0 CAPLUS

CN Acetamide, 2-[(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-45-1 CAPLUS

CN Acetamide, 2-[(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[2-methylphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-46-2 CAPLUS

CN Acetamide, 2-[(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[3-methylphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-47-3 CAPLUS

CN Acetamide, 2-[(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[2-methoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-48-4 CAPLUS

CN Acetamide, 2-[(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[3-methoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 80416-49-5 CAPLUS


CN Acetamide, 2-[(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-
[[(4-chlorophenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1981:407198 CAPLUS
 DN 95:7198
 TI Iodine-substituted 2-hydrazino-3-phenylquinazol-4-ones and their cyclization products. Part 6. Synthesis of compounds with an aminoguanidine structure
 AU Kottke, K.; Kuehmstedt, H.
 CS Sekt. Pharm., Ernst-Moritz-Arndt-Univ. Greifswald, Greifswald, DDR-2200, Ger. Dem. Rep.
 SO Pharmazie (1980), 35(12), 800-1
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 AB Triazoloquinazolones I (X = CR₂, N; R = H, iodo; R₁ = 2-, 3-, 4-iodo, H; R₂ = H, Me, CH₂CO₂Et, OH, SH, Pr, Bu, Ph, CO₂Et) were obtained in 33-100% yield by cyclizing the hydrazines II (R₂ = H) with carboxylic acids or urea. II (R₂ = H) were obtained by hydrazinolysis of the thiols. Treatment of II (R₂ = H) with R₃NCX₁ (R₃ = Ph, 1-naphthyl; X₁ = O, S) gave II (R₂ = CX₁NHR₃).
 IT **77747-37-6P 77747-38-7P 77747-39-8P**
77775-32-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 77747-37-6 CAPLUS
 CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77747-38-7 CAPLUS
 CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



09/724,277 (09/687,800)


RN 77747-39-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 77775-32-7 CAPLUS


CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:405580 CAPLUS
 DN 85:5580
 TI Search for new anthelmintics: part I. Synthesis of quinazolin-4(3H)-on-2-ylthioacetylureas and .alpha.-hydroxybenzylquinazolin-4(3H)-ones
 AU Tiwari, S. S.; Misra, Suman B.
 CS Dep. Chem., Lucknow Univ., Lucknow, India
 SO J. Indian Chem. Soc. (1975), 52(11), 1073-5
 CODEN: JICSAH
 DT Journal
 LA English
 AB The reaction of I (R = SH, R1 = Ph, p-ClC6H4) with R2NHCONHCOCH2Cl gave I (R = R2NHCONHCOCH2S; R1 = Ph R2 = p-anisyl; R1 = p-ClC6H4, R2 = p-anisyl, p-phenetidyl, o-tolyl, p-ClC6H4, PhCH2). Condensation of R1NH2 with 2-(.alpha.-hydroxybenzyl)-3,1(4H)-benzoxazinone gave I (R = PhCHOH, R1 = Ph, o-, m-, p-tolyl, o-, p-anisyl, o-, p-phenetidyl, p-ClC6H4, m-O2NC6H4, o-, p-HOC6H4, PhCH2, cyclohexyl). I (R = 2-MeC6H4NHCONHCOCH2S, R1 = 4-ClC6H4; R = PhCHOH, R1 = 4-MeC6H4) possessed anthelmintic activity in mice at 250 mg/kg.
 IT **59272-21-8P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. and anthelmintic activity of)
 RN 59272-21-8 CAPLUS
 CN Acetamide, 2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[2-methylphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT **59272-18-3P 59272-19-4P 59272-20-7P 59272-22-9P 59272-23-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 59272-18-3 CAPLUS
 CN Acetamide, 2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[4-methoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 59272-19-4 CAPLUS
 CN Acetamide, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)thio]-N-[[4-methoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 59272-20-7 CAPLUS

CN Acetamide, 2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[4-ethoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 59272-22-9 CAPLUS

CN Acetamide, N-[[4-(4-chlorophenyl)amino]carbonyl]-2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]- (9CI) (CA INDEX NAME)



RN 59272-23-0 CAPLUS

CN Acetamide, 2-[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]thio]-N-[[phenylmethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



09/724,277 (09/687,800)

=> d his

(FILE 'HOME' ENTERED AT 16:59:48 ON 18 APR 2002)

FILE 'REGISTRY' ENTERED AT 16:59:53 ON 18 APR 2002

L1 STRUCTURE UPLOADED

L2 2 S L1 SSS SAM

L3 178 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:02:26 ON 18 APR 2002

L4 19 S L3

FILE 'CAOLD' ENTERED AT 17:03:31 ON 18 APR 2002

=> s 13

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.38	226.19

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-11.77

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:03:48 ON 18 APR 2002